Progyny, Inc. PGNY
We take great care to ensure that the data presented and summarized in this overview for Progyny, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PGNY
View all-
Black Rock Inc. New York, NY11.1MShares$313 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.31MShares$233 Million0.01% of portfolio
-
Tpg Gp A, LLC Fort Worth, TX6.6MShares$185 Million5.29% of portfolio
-
Jpmorgan Chase & CO New York, NY3.53MShares$99.2 Million0.01% of portfolio
-
Clearbridge Investments, LLC New York, NY3.5MShares$98.2 Million0.11% of portfolio
-
State Street Corp Boston, MA2.9MShares$81.4 Million0.01% of portfolio
-
Jennison Associates LLC2.6MShares$72.9 Million0.07% of portfolio
-
Fred Alger Management, LLC New York, NY2.36MShares$66.2 Million0.46% of portfolio
-
American Century Companies Inc Kansas City, MO2.23MShares$62.5 Million0.05% of portfolio
-
Riverbridge Partners LLC2MShares$56.1 Million0.96% of portfolio
Latest Institutional Activity in PGNY
Top Purchases
Top Sells
About PGNY
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Insider Transactions at PGNY
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 23
2024
|
Norman Payson Director |
SELL
Open market or private sale
|
Indirect |
200
-0.03%
|
$11,200
$56.29 P/Share
|
|
May 01
2024
|
Michael E Sturmer PRESIDENT |
SELL
Open market or private sale
|
Direct |
4,515
-1.17%
|
$139,965
$31.95 P/Share
|
|
Apr 01
2024
|
Peter Anevski CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
7,977
-3.12%
|
$303,126
$38.15 P/Share
|
|
Apr 01
2024
|
David J Schlanger Executive Chairman |
SELL
Open market or private sale
|
Direct |
1,000
-1.18%
|
$37,000
$37.52 P/Share
|
|
Apr 01
2024
|
David J Schlanger Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
2,681
-3.07%
|
$101,878
$38.15 P/Share
|
|
Apr 01
2024
|
David J Schlanger Executive Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.13%
|
$3,000
$3.95 P/Share
|
|
Apr 01
2024
|
Michael E Sturmer PRESIDENT |
SELL
Open market or private sale
|
Direct |
6,395
-0.82%
|
$236,615
$37.6 P/Share
|
|
Apr 01
2024
|
Mark S. Livingston CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
11,165
-9.37%
|
$413,105
$37.61 P/Share
|
|
Apr 01
2024
|
Mark S. Livingston CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
11,591
-15.91%
|
$428,867
$37.64 P/Share
|
|
Apr 01
2024
|
Mark S. Livingston CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
20,627
+22.06%
|
$61,881
$3.95 P/Share
|
|
Mar 27
2024
|
David J Schlanger Executive Chairman |
SELL
Open market or private sale
|
Direct |
71,272
-45.23%
|
$2,637,064
$37.8 P/Share
|
|
Mar 27
2024
|
David J Schlanger Executive Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
71,272
+31.14%
|
$213,816
$3.95 P/Share
|
|
Mar 26
2024
|
David J Schlanger Executive Chairman |
SELL
Open market or private sale
|
Direct |
305
-0.35%
|
$11,285
$37.5 P/Share
|
|
Mar 26
2024
|
David J Schlanger Executive Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
305
+0.35%
|
$915
$3.95 P/Share
|
|
Mar 25
2024
|
David J Schlanger Executive Chairman |
SELL
Open market or private sale
|
Direct |
2,597
-2.92%
|
$96,089
$37.65 P/Share
|
|
Mar 25
2024
|
David J Schlanger Executive Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
2,597
+2.84%
|
$7,791
$3.95 P/Share
|
|
Mar 21
2024
|
David J Schlanger Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,826
-6.32%
|
$215,562
$37.74 P/Share
|
|
Mar 21
2024
|
David J Schlanger Executive Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
5,826
+5.95%
|
$17,478
$3.95 P/Share
|
|
Mar 11
2024
|
Mark S. Livingston CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
112
-0.3%
|
$3,920
$35.49 P/Share
|
|
Mar 04
2024
|
Michael E Sturmer PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+39.0%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 479K shares |
|---|---|
| Exercise of conversion of derivative security | 1.4M shares |
| Other acquisition or disposition | 282K shares |
| Open market or private sale | 4.38M shares |
|---|---|
| Payment of exercise price or tax liability | 248K shares |
| Bona fide gift | 3.33K shares |
| Other acquisition or disposition | 1.66M shares |